Rosuvastatin reduces nonalcoholic fatty liver disease in patients with chronic hepatitis C treated with α-interferon and ribavirin: Rosuvastatin reduces NAFLD in HCV patients

BACKGROUND: Nonalcoholic fatty liver disease develops in patients with chronic hepatitis C. Interferon and ribavirin combination therapy is the standard treatment for chronic hepatitis C, but if present, NAFLD can reduce the virological response to anti-HCV therapies. OBJECTIVES: We determined wheth...

Полное описание

Сохранить в:
Библиографические подробности
Главные авторы: Malaguarnera, Michele, Vacante, Marco, Russo, Cristina, Gargante, Maria Pia, Giordano, Maria, Bertino, Gaetano, Neri, Sergio, Malaguarnera, Mariano, Galvano, Fabio, Volti, Giovanni Li
Формат: Artigo
Язык:Inglês
Опубликовано: Kowsar 2011
Предметы:
Original Article
Online-ссылка:https://ncbi.nlm.nih.gov/pmc/articles/PMC3206670/
https://ncbi.nlm.nih.gov/pubmed/22087124
Метки: Добавить метку
Нет меток, Требуется 1-ая метка записи!

Схожие документы